DURVALUMAB
Information current as at: 1 July 2026
PBAC meeting date: November 2026
Submission Details
- Brand name:
-
- Imfinzi®
- Form and strength:
-
- Solution concentrate for I.V. infusion 120 mg in 2.4 mL
- Solution concentrate for I.V. infusion 500 mg in 10 mL
- Submission sponsor:
- ASTRAZENECA PTY LTD
- Condition/indication:
(therapeutic use) -
- Non-small cell lung cancer (NSCLC)
- Listing requested:
- To request a change to the existing listing of durvalumab for the treatment of unresectable stage III NSCLC to remove the requirement for a patient to be untreated with immunotherapy at commencement of durvalumab.
- Funding program:
- PBS Section 100 (Efficient Funding of Chemotherapy)
- Request authority level:
- Authority Required (STREAMLINED)
- PBAC Submission type:
- Change to existing listing (–)
- Comment:
- --
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - November 2026 PBAC meeting
-
2Opportunity for consumer comment:
- Open 22/07/2026 and close 16/09/2026 (see PBS Website)
-
3PBAC meeting:
- Has not yet occurred
-
4PBAC outcome published:
- Pending PBAC outcome (see PBAC Outcomes)
-
5Lodgement of required documentation:
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
Case ID
a1274
Page last updated
23 July 2026
v.9.19